Milestones lift Kymera Therapeutics (NASDAQ: KYMR) revenue and support $1.5B cash

Rhea-AI Filing Summary

Kymera Therapeutics reported second-quarter 2026 results, with collaboration revenue of $65.0 million consisting of a $45 million option exercise fee from Gilead and a $20 million milestone from Sanofi. Research and development expenses were $119.5 million and general and administrative expenses were $21.1 million, resulting in a net loss of $61.2 million, or $0.62 per share. Cash, cash equivalents and investments totaled $1.5 billion as of June 30, 2026, and the company expects this cash balance to provide a runway into 2029.

Kymera also outlined rapid progress in its immunology pipeline. Enrollment in the KT‑621 BROADEN2 Phase 2b atopic dermatitis trial was completed nearly six months early, with topline data now expected by year‑end 2026 and Phase 3 trials planned by mid‑2027. The KT‑621 BREADTH Phase 2b asthma trial is ongoing with data expected in late 2027, KT‑579 Phase 1 data are anticipated in the fourth quarter of 2026, and partnered programs KT‑485 with Sanofi and KT‑200 with Gilead advanced into early clinical and IND‑enabling stages.

Positive

• $65.0 million in Q2 2026 collaboration revenue, up from $11.5 million a year earlier, reflecting a $45 million option exercise fee from Gilead and a $20 million milestone payment from Sanofi.
• Ending cash, cash equivalents and investments of $1.5 billion as of June 30, 2026, with the company expecting this balance to provide a cash runway into 2029.

Negative

• None.

Filing Explained

The $20 million milestone created a receivable at June 30 because its cash receipt was reported for the third quarter.

On August 5, 2026, Kymera Therapeutics furnished its second-quarter results; the $20 million Sanofi milestone was recognized as Q2 revenue but was received in Q3, and the June 30 balance sheet lists $20 million of accounts receivable. The structural effect is a timing difference: the reported revenue does not yet represent cash received by the June 30 balance-sheet date.

A Form 8-K reports specified material events, and Item 2.02 covers results of operations and financial condition. This report states that its results release is furnished and is not deemed filed under Section 18 of the Exchange Act.

The filing identifies the third quarter as the receipt period; the corresponding quarterly financial report is the specific place to check whether the $20 million receivable has moved into cash.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 collaboration revenue: $65.0 million Gilead option exercise fee (KT-200): $45 million Sanofi milestone payment (KT-485): $20 million +4 more

7 metrics

Q2 2026 collaboration revenue $65.0 million Collaboration revenues for the quarter ended June 30, 2026

Gilead option exercise fee (KT-200) $45 million Option exercise fee recognized as collaboration revenue in Q2 2026

Sanofi milestone payment (KT-485) $20 million Milestone payment recognized as collaboration revenue in Q2 2026

Q2 2026 research and development expenses $119.5 million Research and development expenses for the quarter ended June 30, 2026

Q2 2026 net loss $61.2 million Net loss attributable to common stockholders in the second quarter of 2026

Cash, cash equivalents and investments $1.5 billion Balance as of June 30, 2026, with expected runway into 2029

Weighted average shares outstanding Q2 2026 98,177,158 Basic and diluted weighted average common shares for the quarter

Key Terms

targeted protein degradation (TPD), atopic dermatitis, hidradenitis suppurativa, milestone payment, +1 more

5 terms

targeted protein degradation (TPD) medical

"pioneering the field of targeted protein degradation (TPD) to develop medicines"

atopic dermatitis medical

"BROADEN2 Phase 2b clinical trial in patients with moderate to severe atopic dermatitis"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

hidradenitis suppurativa medical

"Phase 1 clinical trial evaluating KT-485 in adult healthy volunteers and hidradenitis suppurativa patients"

A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.

milestone payment financial

"dosing of the first participant resulted in a $20 million milestone payment to Kymera"

A milestone payment is a pre-agreed cash amount paid when a company reaches a specific, measurable achievement in a partnership, such as completing a clinical trial stage, receiving regulatory approval, or hitting a sales target. For investors it signals how future revenue and risk are shared — like progress payments on a construction project, these payments can unlock value and affect a company’s cash flow and valuation as each milestone is met.

cash runway financial

"Kymera expects that its cash balance will provide the Company with a cash runway into 2029"

Cash runway is the amount of time a company can continue operating using its available cash before needing additional funding or generating enough revenue. It’s like a countdown showing how long a business can keep running with its current funds. Knowing the cash runway helps investors assess the company's financial health and whether it has enough resources to reach its goals or needs to find more support soon.

Earnings Snapshot

Collaboration revenue: $65.0 million · Guidance included

quarter ended June 30, 2026

Collaboration revenue $65.0 million up from $11.5 million in the second quarter of 2025

Research and development expenses $119.5 million up from $78.4 million in the second quarter of 2025

General and administrative expenses $21.1 million up from $17.6 million in the second quarter of 2025

Net loss $61.2 million improved from $76.6 million in the second quarter of 2025

Cash, cash equivalents and investments $1.5 billion compared with $1.6 billion at December 31, 2025

Guidance

Kymera expects that its cash balance will provide a cash runway into 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/05/2026 - 07:10 AM Accepted by SEC EDGAR 08/05/2026 - 07:10 AM Learn about SEC filing dates

FAQ

What were Kymera Therapeutics (KYMR) collaboration revenues in Q2 2026?

Kymera reported $65.0 million in collaboration revenue in Q2 2026, up from $11.5 million in Q2 2025. This consisted of a $45 million option exercise fee from Gilead and a $20 million milestone payment from Sanofi, both fully recognized in the quarter.

What net loss did Kymera Therapeutics (KYMR) report for Q2 2026?

Kymera reported a Q2 2026 net loss of $61.2 million, or $0.62 per share, compared with $76.6 million, or $0.95 per share, in Q2 2025. Higher collaboration revenue and increased interest income partially offset rising research and development and general and administrative expenses.

How much cash does Kymera Therapeutics (KYMR) have and what is its cash runway?

As of June 30, 2026, Kymera held $1.5 billion in cash, cash equivalents and investments. The company states that this cash balance is expected to provide a runway into 2029, supporting multiple upcoming clinical data readouts and development milestones across its portfolio.

What are the key clinical milestones ahead for Kymera Therapeutics (KYMR)?

Key milestones include KT‑621 BROADEN2 Phase 2b atopic dermatitis data by year-end 2026, planned Phase 3 AD trials by mid‑2027, KT‑621 BREADTH asthma Phase 2b data in late 2027, and KT‑579 Phase 1 data in the fourth quarter of 2026.

What milestone payments did Kymera Therapeutics (KYMR) earn from partners in 2026?

Kymera earned a $45 million option exercise fee from Gilead for licensing KT‑200 and a $20 million milestone from Sanofi tied to dosing the first participant in the KT‑485 Phase 1 trial. Both were recognized as collaboration revenue in Q2 2026.

How did Kymera Therapeutics (KYMR) R&D and G&A expenses change in Q2 2026?

Research and development expenses rose to $119.5 million in Q2 2026 from $78.4 million a year earlier, reflecting investment in STAT6, platform and discovery programs, and R&D headcount. General and administrative expenses increased to $21.1 million from $17.6 million, driven by legal, professional, personnel and facility costs.

0001815442false00018154422026-08-052026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2026

KYMERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39460		81-2992166
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kymera Therapeutics, Inc.

500 North Beacon Street, 4th Floor

Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(857) 285-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trade Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	KYMR	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On August 5, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Kymera Therapeutics, Inc. on August 5, 2026, furnished herewith.
104		Cover Page Interactive Data

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Kymera Therapeutics, Inc.
Date: August 5, 2026		By:		/s/ Nello Mainolfi
				Nello Mainolfi, Ph.D.
				President and Chief Executive Officer

Exhibit 99.1

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

KT-621 Phase 3 trials in AD planned to initiate by mid-2027

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027

KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26

KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi

Well-capitalized with $1.5 billion in cash as of June 30, 2026, and runway into 2029

Company to hold video conference call and webcast today at 8:30 a.m. ET

Watertown, Mass. (August 5, 2026) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the second quarter ended June 30, 2026, and provided business highlights and updates on its pipeline.

“Kymera is delivering in a pivotal period of execution, with multiple clinical-stage programs advancing, important data catalysts ahead, and growing conviction in the potential of oral degrader medicines to transform the standard of care for chronic, debilitating immunological diseases,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “The rapid completion of enrollment in our KT-621 BROADEN2 Phase 2b trial in atopic dermatitis nearly six months ahead of our original timeline is a powerful example of the immense interest from clinicians and patients in a once-daily oral therapy and excellent execution from the Kymera team. The accelerated timeline enables us to pull forward our expected topline readout to year-end 2026, positions us for an earlier than anticipated start to Phase 3 trials next year, and ultimately allows us to move faster for patients who are waiting for new options.”

Dr. Mainolfi continued, “We see the significant gaps that remain across the immunology treatment landscape, and we are hearing directly from clinicians, advocacy groups, patients and their families about the need for effective, safe, and convenient approaches. We remain focused on executing across our differentiated portfolio to address those needs. With KT-621 advancing in both AD and asthma, KT-579 progressing toward Phase 1 data and a planned patient proof-of-concept trial in lupus, and important progress across our partnered programs and early discovery engine, we are translating that urgency into action as we work to deliver a new generation of oral medicines.”

Business Highlights, Recent Developments and Upcoming Milestones

STAT6 Degrader Program

KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is



currently in Phase 2 clinical development in atopic dermatitis (AD) and asthma. KT-621 has the potential to transform treatment for more than 140 million patients around the world suffering from Type 2 diseases such as atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and bullous pemphigoid (BP), among others.

•In June 2026, the Company announced the completion of enrollment in the KT-621 BROADEN2 Phase 2b clinical trial in patients with moderate to severe atopic dermatitis nearly six months ahead of its original timeline. The earlier than expected completion of enrollment enabled the Company to accelerate its expected topline data readout by six months to year-end 2026, earlier than prior guidance to share data by mid-2027. Subject to discussions with regulators, the Company expects to initiate Phase 3 trials in AD by mid-2027.

•Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma. The Company expects to report data in late 2027.

•In June 2026 at the Japanese Dermatological Association (JDA) Annual Meeting, the Company presented results from the KT-621 Phase 1 study in healthy Japanese adults designed to support the enrollment of patients in Japan in global KT-621 studies. KT-621 demonstrated a favorable PK profile, rapid and sustained STAT6 degradation in blood, with median STAT6 degradation of ≥98% at both dose levels, and a favorable safety and tolerability profile. These results are consistent with those observed in non-Japanese healthy adults and atopic dermatitis patients.

•The Company presented data from the KT-621 Phase 1 clinical trials across leading dermatology and respiratory forums, including a late-breaking oral presentation at the Society for Investigative Dermatology (SID) Annual Meeting, an oral presentation at the American Thoracic Society (ATS) Respiratory Innovation Summit, and poster presentations at the Revolutionizing Atopic Dermatitis (RAD) and American Academy of Dermatology (AAD) Innovation Academy meetings.

IRF5 Degrader Program

KT-579 is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and master regulator of immunity, that is currently in Phase 1 testing. KT-579 has the potential to be the first novel mechanism with broad utility in diseases where effective and well tolerated oral therapies are needed, such as lupus, Sjögren's, inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and others.

•Enrollment is ongoing in the KT-579 Phase 1 clinical trial in healthy volunteers, with data expected in the fourth quarter of 2026. The Company plans to initiate a Phase 1b patient proof-of-concept trial in lupus soon after the completion of the healthy volunteer trial.

•The Company presented new preclinical data for KT-579 at the European Alliance of Associations for Rheumatology (EULAR) and Federation of Clinical Immunology Societies (FOCIS) Annual Meetings that demonstrated consistent disease-modifying activity across multiple preclinical lupus models. The Company also presented IBD data at Digestive Disease Week (DDW), where KT-579



demonstrated activity comparable or superior to clinically relevant comparators in a preclinical IBD model.

Partnered Programs

•In June 2026, under its existing collaboration, Sanofi initiated the first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971), an oral, potent and selective second generation IRAK4 degrader, in adult healthy volunteers and hidradenitis suppurativa patients. Under the terms of the collaboration, dosing of the first participant resulted in a $20 million milestone payment to Kymera. KT-485 has the potential to offer a novel oral approach for a variety of chronic immuno-inflammatory diseases. Per the collaboration, Sanofi is leading development, regulatory, and commercial efforts for the program.

•In April 2026, the Company announced that Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera. As a result, Kymera achieved a $45 million milestone payment. KT-200 has the potential to deliver meaningful improvements in the standard of care for patients with breast cancer and other solid tumors. Gilead intends to progress the program into IND-enabling studies to support an IND filing in 2027.

Research

•Leveraging its unique target selection strategy, proven small molecule discovery capabilities, and deep development expertise, the Company continues to advance an early pipeline of novel oral programs with a goal to deliver at least one new development candidate per year.

Corporate

•In June 2026, the Company announced the appointment of Felix J. Baker, PhD, as Chairman of the Board of Directors. Dr. Baker succeeds Bruce Booth, DPhil, who has served as Chairman since co-founding Kymera in 2016 and will remain an Independent Director.

•In July 2026, the Company appointed Terence Rooney, MD, as Chief Medical Officer. Dr. Rooney is an accomplished drug development leader with extensive experience advancing immunology therapies across the full development lifecycle, from early clinical stage through commercialization and franchise expansion. Dr. Rooney will lead Kymera’s global clinical development strategy and guide the advancement of the Company’s oral immunology portfolio. He succeeds Jared Gollob, MD, who retired from his role after eight years of leadership at the Company and will remain as an advisor through the end of the year.

•The Company further strengthened its leadership team with the two important appointments further positioning Kymera to advance its clinical-stage pipeline through its next phase of development and growth. Penny Carlson joined as Senior Vice President, Development Operations, to oversee global clinical development operations. Elizabeth Laws, PhD, joined as Senior Vice President, Development Program Leader, to lead the strategy and global development of KT-621 and the STAT6 franchise.



Financial Results

Collaboration Revenues: Collaboration revenues were $65.0 million for the second quarter of 2026 compared to $11.5 million for the second quarter of 2025. Collaboration revenues recognized in the second quarter of 2026 consisted of a $45 million option exercise fee related to the Company’s collaboration with Gilead Sciences and a $20 million milestone payment related to the Company’s collaboration with Sanofi. Both payments were earned and fully recognized as revenue in the second quarter of 2026. The Company received the $45 million option exercise fee during the second quarter and received the $20 million milestone payment during the third quarter. Collaboration revenues recognized in the second quarter of 2025 were all attributable to the Company’s collaboration with Sanofi.

Research and Development Expenses: Research and development expenses were $119.5 million for the second quarter of 2026 compared to $78.4 million for the second quarter of 2025. This increase was primarily due to increased expenses related to the investment in the Company’s STAT6 program, platform and discovery programs, as well as costs related to continued growth in the research and development organization. Stock based compensation expenses included in R&D were $10.4 million and $8.0 million for the second quarters of 2026 and 2025, respectively.

General and Administrative Expenses: General and administrative expenses were $21.1 million for the second quarter of 2026 compared to $17.6 million for the second quarter of 2025. The increase was primarily due to an increase in legal and professional service fees in support of the Company’s growth and an increase in personnel, facility, occupancy, and other expenses to support growth as a public company. Stock based compensation expenses included in G&A were $8.6 million and $7.4 million for the second quarters of 2026 and 2025, respectively.

Net Loss: Net loss was $61.2 million for the second quarter of 2026 compared to $76.6 million for the second quarter of 2025.

Cash and Cash Equivalents: As of June 30, 2026, Kymera had $1.5 billion in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash runway into 2029 beyond multiple clinical inflection points in its pipeline.

Event Details

Kymera will host a video conference call today, August 5, 2026, at 8:30 a.m. ET. To join the call please use this link to register. A live webcast of the event will be available under News and Events in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.



About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on the development of our clinical and preclinical pipeline, including the therapeutic potential, clinical benefits and safety thereof, the effect of initial parallel development of Phase 2b studies in AD and asthma patients on acceleration of late parallel development across multiple indications, the KT-485/SAR447971 and KT-200 programs, and Kymera’s financial condition and expected cash runway into 2029. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target," “upcoming” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: the risk that preclinical and clinical data, including the results from the Phase 1 trials of KT-621, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate, uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with and submissions to regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements, the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development, and other factors. These risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.



KYMERA THERAPEUTICS, INC.
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
		June 30, 2026		December 31, 2025
Assets
Cash, cash equivalents and marketable securities		$ 1,504,886		$ 1,619,434
Accounts Receivable		20,000		—
Property and equipment, net		39,971		43,175
Right-of-use assets, operating lease		41,100		42,351
Other assets		39,487		37,852
Total assets		$ 1,645,444		$ 1,742,812
Liabilities and Stockholders’ Equity
Deferred revenue		$ —		$ 34,365
Operating lease liabilities		76,141		78,975
Other liabilities		60,047		49,808
Total liabilities		136,188		163,148
Total stockholders’ equity		1,509,256		1,579,664
Total liabilities, preferred stock and stockholders’ equity		$ 1,645,444		$ 1,742,812

KYMERA THERAPEUTICS, INC.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
		Three Months Ended June 30,				Six Months Ended June 30,
		2026		2025		2026		2025
Collaboration Revenue		$ 65,000		$ 11,476		$ 99,365		$ 33,576
Operating expenses:
Research and development		$ 119,481		$ 78,388		$ 217,644		$ 158,643
General and administrative		21,126		$ 17,645		41,484		33,916
Total operating expenses		140,607		96,033		259,128		192,559
Loss from operations		(75,607)		(84,557)		(159,763)		(158,983)
Other income (expense):
Interest and other income		14,477		8,051		29,459		16,968
Interest and other expense		(81)		(108)		(141)		(180)
Total other income		14,396		7,943		29,318		16,788
Net loss attributable to common stockholders		$ (61,211)		$ (76,614)		$ (130,445)		$ (142,195)
Net loss per share attributable to common stockholders, basic and diluted		$ (0.62)		$ (0.95)		$ (1.33)		$ (1.77)
Weighted average common stocks outstanding, basic and diluted		98,177,158		80,449,405		97,857,489		80,298,940



Investor Contact:

Justine Koenigsberg

investors@kymeratx.com

857-285-5300

Media Contact:

Matthew Henson

media@kymeratx.com

857-285-5300

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 170.8 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 31.4 KB